Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amber N McElroy

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Microsystems & Nanoengineering|June 3, 2026
A smartphone-powered decentralized microfluidic platform for sensitive CRISPR-based nucleic acid detectionPeng Zhou, Amber N McElroy, Yingming Xu, et al.
International Journal of Molecular Sciences|June 15, 2017
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient CellsKarolina Skvarova Kramarzova, Mark J Osborn, Beau R Webber, et al.
Stem Cells and Development|August 20, 2016
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi AnemiaMark Osborn, Cara-Lin Lonetree, Beau R Webber, et al.
Research (Washington, D.C.)|January 9, 2026
Beyond Diagnosis: Aerosol Viral Monitoring to Transform Epidemic ResponsesPeng Zhou, Yingming Xu, Amber N McElroy, et al.
Nature Biotechnology|November 11, 2022
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activityMonica E Neugebauer, Alvin Hsu, Mandana Arbab, et al.
International Journal of Molecular Sciences|March 23, 2018
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene OverexpressionMark J Osborn, Christopher J Lees, Amber N McElroy, et al.
Human Gene Therapy|December 30, 2014
Fanconi anemia gene editing by the CRISPR/Cas9 systemMark J Osborn, Richard Gabriel, Beau R Webber, et al.
The Journal of Investigative Dermatology|August 23, 2019
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCsMark J Osborn, Gregory A Newby, Amber N McElroy, et al.
NPJ Regenerative Medicine|March 3, 2017
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosaBeau R Webber, Mark J Osborn, Amber N McElroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Microsystems & Nanoengineering|June 3, 2026
A smartphone-powered decentralized microfluidic platform for sensitive CRISPR-based nucleic acid detectionPeng Zhou, Amber N McElroy, Yingming Xu, et al.
International Journal of Molecular Sciences|June 15, 2017
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient CellsKarolina Skvarova Kramarzova, Mark J Osborn, Beau R Webber, et al.
Stem Cells and Development|August 20, 2016
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi AnemiaMark Osborn, Cara-Lin Lonetree, Beau R Webber, et al.
Research (Washington, D.C.)|January 9, 2026
Beyond Diagnosis: Aerosol Viral Monitoring to Transform Epidemic ResponsesPeng Zhou, Yingming Xu, Amber N McElroy, et al.
Nature Biotechnology|November 11, 2022
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activityMonica E Neugebauer, Alvin Hsu, Mandana Arbab, et al.
International Journal of Molecular Sciences|March 23, 2018
CRISPR/Cas9-Based Cellular Engineering for Targeted Gene OverexpressionMark J Osborn, Christopher J Lees, Amber N McElroy, et al.
Human Gene Therapy|December 30, 2014
Fanconi anemia gene editing by the CRISPR/Cas9 systemMark J Osborn, Richard Gabriel, Beau R Webber, et al.
The Journal of Investigative Dermatology|August 23, 2019
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCsMark J Osborn, Gregory A Newby, Amber N McElroy, et al.
NPJ Regenerative Medicine|March 3, 2017
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosaBeau R Webber, Mark J Osborn, Amber N McElroy, et al.
Nature Communications|December 8, 2019
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editorsBeau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, et al.
Pageof 2